Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...
• Glucagon-like peptide 1 receptor agonists (GLP-1) (medicines used to lower blood glucose) probably reduce the risk of death due to any cause but may have little or no death due to a heart attack in ...
Ocular biomarkers for anemia in diabetic kidney disease include disruption of the external limiting membrane and ellipsoid zone.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback